Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Rating) saw a significant increase in short interest in November. As of November 15th, there was short interest totalling 24,700 shares, an increase of 34.2% from the October 31st total of 18,400 shares. Based on an average trading volume of 90,900 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.3% of the company's shares are short sold.

Analysts Set New Price Targets

Several research firms recently commented on XLO. Raymond James dropped their price objective on Xilio Therapeutics from $31.00 to $13.00 and set an "outperform" rating on the stock in a research report on Thursday, November 10th. Morgan Stanley decreased their price objective on Xilio Therapeutics from $32.00 to $20.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 10th. Finally, Guggenheim decreased their target price on Xilio Therapeutics to $15.00 in a research note on Tuesday, November 15th.

Get Xilio Therapeutics alerts:

Hedge Funds Weigh In On Xilio Therapeutics

Hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its holdings in shares of Xilio Therapeutics by 47.7% in the first quarter. Bank of New York Mellon Corp now owns 21,029 shares of the company's stock valued at $149,000 after purchasing an additional 6,791 shares during the last quarter. State Street Corp grew its position in Xilio Therapeutics by 58.5% in the first quarter. State Street Corp now owns 93,861 shares of the company's stock worth $664,000 after acquiring an additional 34,651 shares during the period. Bailard Inc. purchased a new position in Xilio Therapeutics in the second quarter worth approximately $107,000. Millennium Management LLC purchased a new position in Xilio Therapeutics in the second quarter worth approximately $146,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Xilio Therapeutics during the second quarter worth $220,000. Hedge funds and other institutional investors own 64.66% of the company's stock.

Xilio Therapeutics Trading Down 8.1 %

XLO opened at $2.50 on Wednesday. The firm has a market cap of $68.68 million and a price-to-earnings ratio of -0.74. The company has a current ratio of 8.45, a quick ratio of 8.45 and a debt-to-equity ratio of 0.04. Xilio Therapeutics has a 12 month low of $2.01 and a 12 month high of $20.59. The stock has a fifty day moving average price of $2.54 and a 200-day moving average price of $2.66.

Xilio Therapeutics (NASDAQ:XLO – Get Rating) last posted its quarterly earnings results on Wednesday, November 9th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.17. As a group, equities research analysts anticipate that Xilio Therapeutics will post -3.19 earnings per share for the current fiscal year.

About Xilio Therapeutics

(Get Rating)

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors.

Featured Stories

• Get a free copy of the StockNews.com research report on Xilio Therapeutics (XLO)
• Which Stocks Are Black Friday, Cyber Monday Winners & Losers?
• Three Reasons It's Time To Get Bullish On Organigram
• Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
• Why Investors Are Eating Up Restaurant Brands International
• Zoom Video Continues to Work Through Normalization

Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.